| Customization: | Available |
|---|---|
| Long-Term Storage: | 2ºC- 8ºC, Well-Closed Containers |
| Purity: | >99% |
|
Still deciding? Get samples of US$ 100/Box
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
What is Tirz?
Tirz peptide is a promising compound that has garnered significant attention in the field of medical research due to its potential health benefits. Derived from a combination of glucagon-like peptide-1 (GLP-1) and GIP, tirz has shown remarkable efficacy in improving various health parameters in lab animals. This article delves into the detailed exploration of tirz peptide, its benefits, and potential applications in promoting health and well-being in test subjects.
CERTIFICATE OF ANALYSIS
| Product Name | Tirz (LY3298176) | ||
| Sequence | Tyr-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{Aib}-Leu- Asp-Lys-Ile-Ala-Gln-{diacid-gamma-Glu-(AEEA)2-Lys}-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 | ||
| Quality Standard | In-house | Batch No. | ZB10023106 |
| Batch Quantity | 1013.1g | ||
| Molecular Formula | C225H348N48O | Manufacturing Date | 24-Aug-2023 |
| Molecular Mass | 4813.45 | Retest Date | 24-Aug-2025 |
| Tests | Specifications | Results | |
| Characters | Appearance | White to almost white loose powder | White loose powder |
| Solubility | Soluble in water | Complies | |
| Identifications | HPLC | The retention time of the major peak in the chromatogram of the test solution corresponds to that in the chromatogram of the Reference Solution, as obtained in the Assay | Complies |
| MALDI-MS | 4813.5±1.0 Da | 4812.6 Da | |
| Amino acid analysis | Ser: 4.0-6.0 | 4.6 | |
| Asp: 1.6-2.4 | 1.6 | ||
| Thr: 1.6-2.4 | 1.8 | ||
| Pro: 3.2-4.8 | 4.1 | ||
| Tyr: 1.6-2.4 | 2.1 | ||
| Leu: 1.6-2.4 | 1.9 | ||
| Gly: 3.2-4.8 | 4.0 | ||
| Glu: 3.2-4.8 | 3.8 | ||
| Ala: 3.2-4.8 | 3.9 | ||
| Lys: 1.6-2.4 | 1.9 | ||
| Ile: 2.4-3.6 | 3.0 | ||
| Phe: 1.6-2.4 | 2.2 | ||
| Peptide Purity (HPLC) | ≥ 80% | 93.6% | |
| Related Substances | Impurities (HPLC) | Any unspecified impurity ≤ 0.10% | 0.06% |
| Toal impurities ≤ 0.50% | 0.12% | ||
| Oligomer | ≤ 3.0% | 0.27% | |
| Water content (KF) | ≤ 8.0% | 4.63% | |
| Sodium ion | Report | 1.1% | |
| Residual solvents (GC) | Acetonitril-e ≤ 410 ppm | 246 ppm | |
| Bacterial Endotoxins | ≤ 10 EU/mg | Complies | |
| Microbiology | Total aerobic microbial count | ≤ 100 CFU/g | < 10 CFU/g |
| Total combined yeasts and moulds count | ≤ 100 CFU/g | < 10 CFU/g | |
| Escherichia coli count | Absent in 1g | Complies | |
| Assay | Calculated as C18H14F4N2O4S on dried substance | 98.0% - 102.0% | 99.8% |
| Storage condition: | 2°C - 8°C, well-closed containers, protected from light. |
| Remarks: | This batch of product COMPLIES with the prescribed standards. |
| Analysed on: | 18.09.2023 |
FAQ
1. How to preserve peptides after receiving them?
Peptides in the form of lyophilized powder can be transported at room temperature by vacuum packaging, while polypeptides in the dissolved state need to be refrigerated at 2°C - 8°C. For long-term storage, peptides should be stored in the form of lyophilized powder stored at -20°C or -80°C in a sealed container with desiccant, which can avoid the degradation of peptides to the greatest extent.
| # | Product | Sequence | Therapeutic Area | Form | Unit Size |
| 4109712 | Sema | H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEAc-AEEAc-γ-Glu-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH | Type II diabetes mellitus Obesity |
Lyophilized powder | 2 mg/vial 5 mg/vial 10 mg/vial 15 mg/vial 20 mg/vial 1 g/tube |
| 4109713 | Tirz | H-Tyr-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{Aib}-Leu-Asp-Lys-Ile-Ala-Gln-{diacid-gamma-Glu-(AEEA)2-Lys}-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 | Type II diabetes mellitus Obesity |
Lyophilized powder | 10 mg/vial 15 mg/vial 20 mg/vial 30 mg/vial 60 mg/vial 1 g/tube |
| 4109714 | Cagri | {Eicosanedioic acid-γ-Glu}-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Glu-Phe-Leu-Arg-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Pro-NH2 | Type II diabetes mellitus Obesity |
Lyophilized powder | 5 mg/vial 10 mg/vial 1 g/tube |
| 4109715 | CagriSema | Blend | Type II diabetes mellitus Obesity |
Lyophilized powder | 5 mg/vial 10 mg/vial 20 mg/vial 1 g/tube |
| 4109716 | Reta | Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{α-Me-Leu}-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 | Treatment of type 2 diabetes Treatment of obesity |
Lyophilized powder | 8 mg 10 mg 12 mg 15 mg 1 g/tube |
){kind=link}